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Background: Minocycline, a member of the tetracycline family, has a low risk of adverse effects and an ability to
improve behavioral performance in humans with cognitive disruption. We performed a single-arm open-label trial
in which 25 children diagnosed with Angelman syndrome (AS) were administered minocycline to assess the safety
and tolerability of minocycline in this patient population and determine the drug? s effect on the cognitive and
behavioral manifestations of the disorder.
Methods: Participants, age 4-12 years old, were randomly selected from a pool of previously screened children for
participation in this study. Each child received 3 milligrams of minocycline per kilogram of body weight per day for
8 weeks. Participants were assessed during 3 study visits: baseline, after 8-weeks of minocycline treatment and after an
8-week wash out period. The primary outcome measure was the Bayley Scales of Infant and Toddler Development 3rd
Edition (BSID-III). Secondary outcome measures included the Clinical Global Impressions Scale (CGI), Vineland Adaptive
Behavior Scales 2nd Edition (VABS-II), Preschool Language Scale 4th Edition (PLS-IV) and EEG scores. Observations were
considered statistically significant if p < 0.05 using ANOVA and partial eta squared (η2) was calculated to show effect
size. Multiple comparisons testing between time points were carried out using Dunnett? s post hoc testing.
Results: Significant improvement in the mean raw scores of the BSID-III subdomains communication and fine motor
ability as well as the subdomains auditory comprehension and total language ability of the PLS-IV when baseline
scores were compared to scores after the washout period. Further, improvements were observed in the receptive
communication subdomain of the VABS-II after treatment with minocycline. Finally, mean scores of the BSID-III
self-direction subdomain and CGI scale score were significantly improved both after minocycline treatment and
after the wash out period.
Conclusion: The clinical and neuropsychological measures suggest minocycline was well tolerated and causes
improvements in the adaptive behaviors of this sample of children with Angelman syndrome. While the optimal
dosage and the effects of long-term use still need to be determined, these findings suggest further investigation into
the effect minocycline has on patients with Angelman syndrome is warranted.
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First described in 1965, children with Angelman syndrome
(AS, DOID_1932) present clinically with physical features
such as microcephaly and a puppet like gait as wells
as profound developmental delays and little vocal
communication ability [1-5]. While these patients exhibit
a happy demeanor and easily provoked laughter, this
syndrome also consists of other manifestations including
hyper-excitability, poor motor function, and delays in
adaptive behaviors. Furthermore, patients with AS exhibit
EEG patterns specific to the syndrome, and when present
in the appropriate clinical context, help in diagnosing
the syndrome earlier. Finally, 90% of children diag-
nosed with AS suffer from seizure of various types
and severity [3,6-12].
Angelman syndrome is unique in that nearly all cases
result from the disruption of a single gene, UBE3A
[13,14]. Previous research in both the AS mouse model
and humans with AS show no gross morphology changes
in brain. However, the absence of the protein product,
UBE3A, a E3 ubiquitin ligase, results in the accumulation
of regulatory proteins, such as arc and ephexin 5 in the
postsynaptic density, which is believed to cause abnormal
dendritic spine morphology (filopodial) and density in
hippocampal pyramidal neurons leading to aberrant
synaptic function [15,16]. These alterations in spine
morphology and synaptic function in neurons provides an
explanation for the severe behavioral and cognitive
manifestations of the syndrome. Our laboratory has
recently reported the application of Reelin, a protein
shown to increase dendritic spine density, enhanced
cognition in a mouse model [17]. Further, other researchers
have recently reported the recovery of the cognitive and
behavioral deficits associated with AS and even the
commencement of UBE3A protein production when
certain therapeutics such as UBE3A viral vectors and
topoisomerase inhibitors were applied [18-20]. It stands to
reason then, a therapeutic with the ability to normalize
the aberrant synaptic function underlying AS could
ameliorate the severity of symptoms.
Minocycline hydrochloride (MC) is a small (495 kDa),
lipophilic, second-generation tetracycline antibiotic medi-
cation that readily crosses the blood brain barrier [21].
These characteristics allow minocycline to penetrate the
central nervous system more readily than other members
of the tetracycline family [22]. As with the aforementioned
therapies, minocycline has been shown to recover
synaptic dysfunction through the modulation of dendritic
spine structure by reducing the activity of matrix
metalloproteinases [23]. Previous research has shown the
incubation of neuronal cultures with MMP-9 altered
dendritic spine shape and number. Moreover, increases
in both protein level and activity of the MMP? s occurs in
models of epilepsy, which is prevalent in the AS population[12]. Further, minocycline changes the morphology of
dendritic spines in hippocampal neurons from elongated
(immature) to mushroom-shaped (mature), ultimately
rescuing the synaptic defect and improving spatial
memory [23].
Interestingly the application of minocycline has been
shown to act on numerous other aspects of the CNS. The
drug has been shown to be neuroprotective, anti-apoptotic,
and anti-inflammatory [24-26]. Beyond this, minocycline
can positively alter the AMPA-type glutamate receptor
[27-29], metabotropic glutamate receptor 1 and 5 [30,31]
and NMDA receptor function [30,32]. Metabotropic glu-
tamate receptors, AMPA receptors and NMDA receptors
are known to be important in overall neuronal function
and contribute to the synaptic plasticity defect in the AS
mouse model [31,33-35].
Minocycline has also been used as a treatment of other
human cognitive disorders. For example, when MC was
administered to patients with Fragile X syndrome (FRX),
significant behavioral improvement in the subscale
scores of the Aberrant Behavior Checklist-Community,
as well as the Visual Analog Scale and Clinical Global
Impressions Scale scores were reported with only minor
adverse effects observed [36]. Studies of the drug ? s effect
on degenerative neuropathology (e.g., Alzheimer ? s and
Parkinson ? s disease, Amyotrophic Lateral Sclerosis) have
shown the administration of minocycline reduces the
severity and progression of disease and, in some cases,
prolongs the lifespan of animal models [37,38].
Preclinical electrophysiological studies were carried
out in a mouse model of AS (RRID:IMSR_JAX:004477)
after 21 days of minocycline treatment. We found a
full recovery of the synaptic plasticity defect normally
observed in the AS mouse model (Figure 1) [20]. We,
and others, have shown a reduction in synaptic plasti-
city in the hippocampus, cerebellum and visual cortex
in the AS mice [34,35,39]. Therefore, recovery of the
synaptic plasticity defect was a significant finding for
this therapeutic.
The precise mechanism of minocycline, beyond its
antibacterial mechanism, is unknown. However, this
has not precluded the investigation of minocycline
(with associated benefit) on human neurological dis-
eases such as Alzheimer ? s, Parkinson ? s, Stroke, trau-
matic brain injuries and Fragile X syndrome [36-38].
The results of the above mentioned studies led us to
posit that administering minocycline to patients with
Angelman syndrome may ameliorate the central ner-
vous system symptoms associated with the syndrome
and improve behavioral performance. Here, we re-
port the changes in symptom severity, cognition, and
adaptive behavior after a sample of 25 children with
Angelman syndrome were administered minocycline
for 8 weeks.
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Figure 1 Minocycline restores the synaptic plasticity defect in the AS mouse model. 3-month-old UBE3A maternal deficient (AS) mice
show increase in long-term potentiation (LTP) after 21 days of treatment with minocycline. Field extracellular postsynaptic potentials (fEPSPs) were
recorded and their slopes are conveyed as a percentage of the pre-theta burst stimulation (TBS) baseline. Representative traces before (bold) and
30 minutes after TBS are shown for saline treated (control) and minocycline treated AS mice.
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Study design
This study took place at the University of South Florida
and was approved by USF? s Human Research Protection
Program? s Institutional Review Board (Pro00004716).
The USF IRB issued a waiver of assent; however written
informed consent was obtained from both the mother
and father of each participant. Since no previous
research existed showing how children with AS would
respond to minocycline, statistical methods could not be
employed to determine sample size. Therefore, human
subject protections mandated a single arm open-label
study design be implemented with no placebo control.
After baseline testing (T1), 25 children with AS were pre-
scribed minocycline for 8 weeks. Concurrent administra-
tion of medication necessary for seizure control or other
comorbid conditions was allowed. The time course and
dosing was determined from previous research in which
children with FRX were administered minocycline [36].
The study participants were evaluated again after 8 weeks
of treatment (T2) and 8 weeks after minocycline was
discontinued (T3). The objective of this study was to
evaluate the tolerability of minocycline in children
with AS and provide preliminary neuropsychological
and electroneurophysiology data.
Recruitment
Participants of this study were recruited through the websites
of Angelman parent organizations and clinicaltrials.gov.Children that met the screening criteria were pooled and
participants were selected at random using a com-
puter generated randomization schedule (SAS, Cary, NC).
To minimize the chance of screen failure, parents were
required to have their child? s primary care provider or
neurologist complete a short questionnaire attesting
the child met the inclusion criteria and provide an
indication of the severity of the child? s disability due to
Angelman syndrome.
Inclusion criteria included: 1) A molecularly confirmed
diagnosis of Angelman syndrome. 2) Male or female. 3)
Age between 4 to 12 years old at the time of recruitment.
4) A CGI-S score of 4 or greater indicating at least moderate
severity of symptoms. 5) An acceptable surrogate capable
of providing consent on the participant? s behalf.
Exclusion criteria included: 1) A known allergy to mino-
cycline or any tetracycline. 2) No molecular confirmation
of the AS diagnosis. 3) Participation in another study in
which a drug, vitamin or dietary manipulation was used to
treat AS within 6 months preceding enrollment. 4) Severe
or uncontrolled seizures or any other medical condition
rendering the child medically unstable. 5) A history of
cardiovascular, respiratory, liver, kidney or hematologic
disease or a history of systemic lupus erythematosus.
Medical and neuropsychological evaluation
Each participant underwent 3 identical study visits con-
sisting of medical evaluation and neuropsychological
examination at baseline, after 8 weeks of treatment with
Table 1 A summary of adverse events
Participant Description of symptoms Latency toonset (Days)
1 Feminine Yeast Infection 24a
2 Seizure - Atypical Absence 56a
3 Commencement of Menstruation 27a
4 Difficulty Standing & Balancing 63
5 Dark Spots on Shins 18a
8 Lethargy/Sleepiness 18a,b
10 Sleepiness 20a,b
11 Diagnosis of Lyme Disease 112
13 Urinary Tract Infection 57
15
Seizure - Tonic-Clonic & Difficulty
Ambulating
9a
21 Influenza Type A 57
22 Sleepiness and Difficulty Ambulating 39a,b
24 Seizure 110c
25 Seizure Associated with Fever & Vomiting 113
aAdverse event occurred during minocycline treatment.
bParticipant required a dose adjustment.
cSubject withdrew due to adverse event.
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A board-certified pediatric neurologist completed a
detailed history and physical examination, assigned a
Clinical Global Impressions ? Severity (CGI-S) score and
interpreted the results of laboratory testing. Blood screening
included a complete blood count (CBC), as well as blood
urea nitrogen (BUN), creatinine, alanine amino transferase
(ALT), and aspartate aminotransferase (AST) levels. Finally,
a 30-minute electroencephalogram completed the medical
evaluation. Neuropsychological measures were administered
during each study visit. These outcome measures included
the Bayley Scales of Infant and Toddler Development 3rd
Edition (BSID-III), Vineland Adaptive Behavior Scales, 2nd
Edition (Vinland-II), and Preschool Language Scale, 4th
Edition (PLS-IV). To ensure compliance with the dosing
regimen, caregivers were asked to record the date and time
each dose of minocycline was administered.
Safety and adverse event monitoring
Prior to the initiation of any study procedures both parents
(or the legally authorized representative) of participants
were required to sign an informed consent document in
person. The document detailed all of the study procedures
and each of the known side effects of minocycline. During
the course of the study, caregivers were asked to report any
observed side effects and/or changes in behavior immedi-
ately via telephone. After 4 and 8-weeks of minocycline
treatment as well as 4 and 8-weeks after the drug was
discontinued caregivers were asked to complete online
questionnaires to document adherence to the medication
regimen and to document any observation the caregiver my
have made. To assess the safety of minocycline on multiple
organ systems, the aforementioned blood-screening tests
were reviewed during each study visit. When an adverse
event was reported, the duration, severity, relatedness and
treatment status were documented (Table 1).
Minocycline dosing
After baseline testing, each subject was prescribed minocy-
cline according to his or her body weight (3 mg/kg/day, not
exceeding 200 mg a day). The drug was dispensed in 50 mg
caplets to be taken orally twice daily (BID). While the lack
of speech made it difficult to discern, 3 participants taking
200 mg per day appeared to suffer from intolerable lethargy
and/or dizziness (Table 1). The adverse effects resolved
when the dose was reduced to 100 mg daily. The dosages
used here are equivalent to those used in clinical practice
for children greater than 8 years of age and have
been established as tolerable and safe in similar patient
populations [40,41].
Statistical analysis
For each dependent measure, the effect of minocycline
treatment was assessed using repeated measures analysisof variance (ANOVA) with P values of less than 0.05
considered significant. Post hoc Dunnett ? s tests were
performed to isolate significant changes from baseline
assessment values. A 2 ? 3 mixed factor ANOVA was
performed with age (≤9 or >9 years old) as a between
groups measure and assessment time as a repeated measure.
For all analyses, partial η2 (effect size) was calculated
according to the guidelines of Cohen (0.01 = small effect,
0.06 =moderate effect, 0.14 = large effect) [42].
Primary outcome measures
Bayley Scales of Infant and Toddler Development, 3rd
Edition was administered consistent to the test manual,
under the direct supervision of a board-certified neuro-
psychologist, and by a single pyschometrician who was blind
to the purpose and phase of the study. The BSID-III is a
measure of development used to assess the cognitive,
language and motor abilities of children ages 1 to 42 months.
The BSID-III yields scores for five developmental domains:
Adaptive Behavior (self-care and self-direction), Cognitive
(attention, memory, sensorimotor, and visual preference),
Language (receptive and expressive language functions),
Motor (fine and gross motor) and Social-Emotional
(using emotional signals for self regulation and communi-
cation needs). Internal reliability of the BSID-III is high,
ranging from 0.086 to 0.93 in healthy subjects. We chose
to administer this test because: 1) it has been shown to be
reliable and valid with high correlation coefficients for
test-retest reliability in children with other neuropathologies
[43]; 2) the BSID-III is a common data element suggested
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research involving children with Epilepsy, stroke and other
neurologic disorders [44]; and 3) literature suggests the
BSID-III is an appropriate measure to use in children, such
as those with AS, that exhibit profound developmental
delays [45-47]. Under normal circumstances raw scores are
converted to standard scores based on age-matched healthy
normative data. Children in this sample exhibited
raw scores that were well below age-matched peers
performances, which would result in standard scores
at the floor of the distribution. Past research using
the BSID-II in children with AS reported raw scores.
Moreover, reporting raw scores adheres to the STROBE
reporting guidelines [48]. Finally, utilizing raw scores may
better reflect clinical change in functional ability that
could be observed for children with profound neurocogni-
tive deficits (e.g., increase in the number of spoken words,
or initial expression of speech) that remains far below
expectations for age-matched healthy peers and not
reflected in standardized scores. Therefore, this study
employed raw scores to provide a quantitative assessment
of skills and abilities of the BSID-III domains in our
analyses [45,49].
Secondary outcome measure
The secondary outcome measures include the Vineland
Adaptive Behavior Scales 2nd Edition (VABS-II) and the
Preschool Language Scale 4th Edition (PLS-IV). The
VABS-II is a designated NIH common data element for
assessment of adaptive skills across 4 behavioral domains:
communication, daily living skills, socialization, motor
ability and also assesses maladaptive behaviors. Scores are
based on subjective ratings of parent ? s/primary care
provider's perception of a child ? s ability to complete
various behaviors/tasks. The VABS-II was designed for
special needs children, including those with intellectual
disabilities, autistic spectrum disorders and ADHD. The
test provides normative data for individuals from birth to
age 90 years old. Internal reliability for early childhood,
birth through 36 months, is 0.79 to 0.95 and varied from
0.83 to 0.93 for children aged 4 to 5 years old. Inter-rater
reliability of two different caregivers for the same
individual aged birth to 6 years old were moderate to
large, ranging from 0.61 to 0.82. [47,50,51]. The PLS-IV is
well-recognized interactive, play-based comprehensive
assessment of developmental language for children aged
birth to 7 years, 11 months of age. Assessment provides
scores for Total Language Ability, Auditory Comprehen-
sion and Expressive Communication. Internal reliability of
measures are generally high, ranging from 0.80 to 0.97.
Both the Vineland-II and the PLS-IV have been used
extensively in research evaluating developmental language
deficits across a variety of developmental disabilities,
including Angelman syndrome [52].Clinical assessment
A physical examination and EEG assessment was performed
at baseline (T1), after 8 weeks of minocycline treatment
(T2) and after an 8-week washout period (T3). At every
time point, a board-certified pediatric neurologist utilized
the clinical global impressions severity scale to rate the
severity of the participant?s condition, where 0 represents no
symptoms and 7 the most severe symptoms. This scale
provides a quantitative measure of symptom severity that
allows the clinician to take into account the participant?s
history, symptoms, behavior and how his or her disability
impacted daily living before and after treatment [53].
A routine 21-channel EEG study was performed utilizing
a standard 10/20 system of electrode placement. 30 to
60 minute EEG recordings in the awake and, whenever pos-
sible, asleep states were obtained without sedation. Asleep
EEG recordings could only be obtained from 3 participants
at various time points. After the conclusion of the study,
each EEG recording was de-identified, and placed in ran-
dom order so that the EEG order and relation to treatment
were not known. A scoring system was used to evaluate
several aspects of the EEG recordings regardless of whether
or not they were a part of AS specific EEG patterns. Points
were assigned when a particular characteristic was observed.
For example, 1 point was given if an EEG was abnormal
overall. Characteristics that would be considered more
abnormal were scored accordingly. For instance, when
evaluating the EEG background, 1 point was assigned if
primarily theta waves (mild slowing, >50%) were observed.
When a mixture of theta and delta waves (moderate
slowing) were observed, 2 points were assigned. Finally,
when primarily delta waves (severe slowing, >50%) were
recorded 3 points were assigned. Other EEG characteristics
were also examined including occipital rhythm (normal-1,
slow-2 and absent-3), rhythmic theta (present <50% of
the time-1, present >50% of the time-2), rhythmic delta
(present-3) and epileptiform abnormalities (present-1,
focal-1, multifocal-1, generalized-1, seizure-2). The points
were totaled resulting in a total score, ranging from 0
(most normal) to 24 (most abnormal).
Results
Study Participants: 11 female and 14 male children, mean
age 8.2 years old, were enrolled in the study. Of those
enrolled, 21 participants were confirmed to have a
maternal deletion (the number of deleted bases was
variable) and 4 were positive for a mutation of the
UBE3A gene. Twenty-four children completed the 16-week
open-label study; one participant withdrew at week 16 due
to unrelated seizure activity.
Primary outcome measure
A significant improvement in raw scores of the communi-
cation subscale of Bayley-III (Table 2) was observed at T3
Table 2 Neuropsychological outcome measures
Bayley Scales of Infant and Toddler Development, 3rd Edition
Cognitive Communication Language Motor Self
Receptive Expressive Gross Fine Care Direction
T1 26.4 ? 2.48 18.9 ? 1.60 13.4 ? 0.61 10.1 ? 0.76 41.3 ? 1.69 19.4 ? 1.05 37.8 ? 1.81 33.8 ? 2.24
T2 31.7 ? 1.83 22.8 ? 1.69 13.7 ? 0.81 11.8 ? 0.75 40.5 ? 1.60 19.8 ? 1.47 40.6 ? 1.84 *38.1 ? 1.98
T3 30.7 ? 2.09 *23.5 ? 1.88 13.8 ? 0.68 11.2 ? 0.68 42.8 ? 1.12 ? 22.4 ? 1.5 40.0 ? 1.99 *39.5 ? 1.94
η2 0.05 0.05 0.002 0.04 0.02 0.03 0.02 0.06
Vineland Adaptive Behavior Scales, 2nd Edition
Maladaptive Behavior Communication Motor Daily Living Skills
Internal External Receptive Expressive Gross Fine Personal Domestic
T1 6.7 ? 0.44 5.5 ? 0.58 30.3 ? 1.62 41.8 ? 3.02 48.3 ? 3.27 99.0 ? 7.12 53.8 ? 5.61 2.6 ? 0.95
T2 5.5 ? 0.47 4.7 ? 0.57 *36.4 ? 2.42 44.3 ? 3.23 48.9 ? 3.32 101.2 ? 7.5 59.1 ? 5.75 3.8 ? 1.49
T3 5.7 ? 0.52 6.0 ? 1.25 33.9 ? 2.25 43.8 ? 2.58 49.4 ? 3.25 95.4 ? 7.84 56.4 ? 4.95 2.7 ? 0.92
η2 0.05 0.02 0.06 0.06 0.001 0.004 0.007 0.01
Preschool Language Scale, 4th Edition
Auditory Comprehension Total Language Expressive Communication
T1 17.64 ? 0.68 34.20 ? 1.58 16.3 ? 1.14
T2 18.25 ? 0.58 34.88 ? 1.36 16.6 ? 0.94
T3 *20.48 ? 0.71 *38.83 ? 1.34 17.5 ? 0.71
η2 0.13 0.08 0.001
Mean ? Standard Error.
η2 (Partial Eta squared) is a measure of effect size. 0.01 suggests a small effect, 0.06 a medium effect and 0.14 a large effect.
*p < 0.05 when the time point is compared to T1 (baseline).
? p < 0.05 when the time point is compared to T2 (after treatment with minocycline).
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hoc analysis revealed scores from participants between
the ages of 4 and 9 years old were responsible for a
40% increase, while scores from participants between ages
9 and 12 years of age remained unchanged. Moreover, a
significant improvement, F(2,46) = 5.011, p < 0.05, of the
subscale self-direction was observed at both T2 and
T3, compared to T1. While no change was observed
in gross motor ability, a significant increase (15%) in
the measure of fine motor ability was observed at T3,
F(2,46) = 3.28, p < 0.05.
Neuropsychological outcomes
A significant improvement in the raw scores of the
receptive communication index of the Vineland-II was
found between T2 and baseline, F(2,46) = 6.73, p < 0.05.
Two domains of the PLS-IV, auditory comprehension and
total language ability, were both found to have increased
significantly when measures at T3 were compared to
baseline, F(2,44) = 6.73, p <0.05 and F(2,44) = 5.84, p <0.05,
respectively.
Clinical outcomes
Blood screening tests showed no clinically significant
changes over the 16-week study course and no serious
adverse effects related to minocycline treatment werereported (Table 1). In 3 cases, caregivers reported
lethargy and/or dizziness that required a dose adjustment
and was considered related to the minocycline treatment.
All of these participants were receiving 100 mg of
minocycline BID. In 2 other cases, caregivers reported
difficultly standing and/or walking that resolved after
the discontinuation of minocycline. Significant clinical
improvement over baseline, for all participants, as measured
by the CGI-S score (Table 3), was observed at T2 and
T3 [F(2, 46) =13.20, p < 0.05]. Analysis of EEG scores
revealed a 4.3% and 10.8% improvement when T2 and T3
observations were compared to baseline but did not reach
the level of significance [F(2,46) = 1.494, p > 0.05]. For
both measures, calculated partial η2 was equal to 0.05, an
indication of a moderate effect size.
Discussion
To our knowledge, this is the first prospective trial of
minocycline treatment in which safety, tolerability,
cognitive function and adaptive behavior were evaluated
among children with Angelman syndrome. Statistically
significant changes were observed across several subscales
with moderate relative effect sizes (Table 2) in both the
primary and secondary outcome measures for language,
communication and self-direction. When the mean scores
for all participants were analyzed, a significant improvement





T1 T2 T3 T1 T2 T3
1 Female 100 200 5 4 5 4 7 4
2 Male 88 100 4 4 4 8 9 6
3 Female 124 200 7 6 7 11 7 12
4 Female 128 200 6 5 5 14 12 11
5 Male 119 100 4 4 3 5 5 3
6 Male 160 200 5 4 5 6 6 6
7 Female 89 100 5 5 5 5 9 5
8 Female 101 200 5 5 5 8 5 9
9 Male 60 100 6 5 6 15 9 12
10 Male 86 200 4 4 4 8 8 6
11 Female 89 100 5 5 5 12 9 8
12 Female 112 200 4 3 3 9 8 5
13 Female 111 100 6 4 4 9 9 6
14 Male 76 200 6 6 6 9 9 8
15 Male 127 200 6 5 6 6 6 4
16 Male 63 100 7 6 6 14 11 16
17 Female 72 100 5 4 5 14 12 12
18 Female 83 100 5 4 3 9 9 9
19 Male 97 100 5 4 4 5 7 11
20 Male 125 200 5 5 5 10 15 3
21 Male 130 200 7 7 7 10 9 10
22 Male 148 200 8 7 7 4 3 8
23 Male 120 200 5 5 5 14 13 13
24 Male 87 100 7 7 - 7 9 -
25 Female 85 100 7 6 7 13 13 9
Mean ? Standard Deviation 5.56 ? 1.12 *4.96 ? 1.10 *5.08 ? 1.25 9.16 ? 3.47 8.76 ? 2.80 8.16 ? 3.47
Standard Error of the Mean 0.224 0.220 0.255 0.694 0.561 0.709
η2 0.05 0.05
η2 (Partial Eta squared) is a measure of effect size. 0.01 suggests a small effect, 0.06 a medium effect and 0.14 a large effect.
*Indicates p < 0.05 when the time point is compared to T1 (baseline).
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Participants also showed a significant improvement in
self-direction, the ability to entertain themselves and
follow simple directions, after being treated with minocy-
cline. This suggests minocycline may have positive effects
on language, fine motor skills and some adaptive behaviors.
While raw scores had to be used considering the cognitive
and language deficits of these children, the improvements
in cognition, language and motor skills were perceived by
caregivers as shown by the VABS-II results. These
pilot data show minocycline may improve the pervasive
cognitive and language deficits of these patients over
a 16-week period.
The effects of minocycline were also observed clinically
as shown by clinician rated function (CGI-S) scores. Nochange in the EEG scores was observed. However, this
was measured with consistent anti-seizure medication and
concurrent treatment of minocycline. Thus, it is unclear
whether minocycline has an effect on EEG patterns of AS
patients not receiving treatment for seizure. Caregivers
reported few adverse effects and no severe adverse events
related to minocycline treatment. Language limitations
required adverse event reports from caregivers rather
than participants themselves. In 3 cases, lethargy and/or
dizziness was reported in participants taking 200 mg of
minocycline daily. These symptoms subsided after the
dosage was reduced, suggesting a smaller dosage may be
required to mitigate adverse effects. We show statistically
significant results after MC treatment was discontinued
(T3) suggesting a lasting treatment effect. However,
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Therefore, further study is needed to determine the
optimal length of treatment and what effect extended
exposure to minocycline may have in the AS patient
population. In general, these data suggest the short-term
use of minocycline at these dosages in children with AS is
well tolerated.
Several notable limitations of this pilot study include
the behavioral manifestations of the participants, single
arm study design, lack of control for practice effect,
and small sample size. As expected, the behavioral
characteristics of the participants (low tolerance for
frustration, limited language skills, articulation patterns
that made speech intelligible only to caregivers) interfered
with their performance on the neuropsychological
instruments. However, these behavioral deficits reflect
the severe cognitive and language impairments of
these individuals and account for their below age
level skills in self-care and social behaviors. Moreover,
the preponderance of the testing consists of questionnaires
and relies on parent responses that may include bias.
Regardless, we chose to employ the same neuropsycho-
logical instruments used in previous studies of AS
patients. This includes the Bayley Scale of Infant and
Toddler Development ? 3rd Edition despite the age
limit of 42 months.
Future research to explore therapeutic benefits of
minocycline in AS should involve studies with a
placebo-controlled crossover design to better control
for practice and temporal effects. The study design
also did not allow for evaluation of practice effects
particularly from T1 to T2. Previous research is replete
with data indicating practice effects are present in
neuropsychological assessments and are often most
pronounced between first and second testing periods
and decrease from second to third testing periods. It
is important to point out that there are no published
results studying practice effect in children with Angelman
syndrome. Moreover, the calculated η2, the results reported
here show the associated improvement in neuropsycho-
logical measures reflected an actual treatment effect not
attributable to practice or error.
Conclusion
The data reported here show the administration of
minocycline to children with Angelman syndrome is
safe and well tolerated. Moreover, we show minocycline
improved the adaptive behavior of these children suggest-
ing this drug may be an effective treatment of this disorder.
It is important to determine the optimal treatment dosage
as well as the effects of long-term use in this patient
population. Therefore, future controlled studies are
recommended before minocycline is used generally as
a treatment for Angelman syndrome.Competing interests
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